There are many methods to make tumor dormant. Unlike conventional treatment, any dormant treatment is subject to the safety of normal cells of the body. At present, some palliative methods of tumor reduction do not have the effect of dormant tumor. For example, surgical removal of some tumors can achieve the purpose of tumor reduction, but because of its inhibitory effect on active cancer cells, it does not make the residual tumors dormant. In addition, surgery is a huge trauma to the body, which can destroy the conditions of survival of the body with tumor. Radiation therapy is also a kind of tumor reduction, because radiation itself can also destroy normal cells, so it requires low dose and uninterrupted course of treatment, and the therapeutic effect does not pursue the disappearance of tumor necrosis, but to make the cancer cells in a state of suppression after radiation, so as to achieve the effect of making the tumor dormant. The most common method of tumor dormancy is chemotherapy, but unlike traditional chemotherapy, it does not require the reduction or disappearance of solid tumors through chemotherapy, but rather moderate chemotherapy to stop the active growth and invasion front of cancer cells and keep them in an inactive state. It has been proven that cancer is a genetic disease. Normal cells in the human body are sperm and egg fertilized, and after many repeated divisions and proliferations, some cells stop proliferating, i.e., they enter a dormant state. Regulating this proliferation are signaling system, apoptosis, telomeres, etc. Cancer is due to multiple genetic abnormalities that cause the dormant structures to break down and restart the infinite proliferative state. Moreover, it acquires the ability of revascularization and infiltration, and becomes more malignant and accompanied by lethal metastasis. Therefore, the fundamental treatment of cancer is not to kill the significantly growing cells, but to make them dormant and become mildly inactive again. Almost all chemotherapeutic agents do not recognize cancer cells but only kill rapidly proliferating cells non-specifically. Therefore, conventional chemotherapy can also kill normal cells that proliferate rapidly, such as bone marrow cells, digestive tract mucosa and hair, causing side effects such as bone marrow suppression, vomiting, diarrhea and hair loss in patients. By simply pursuing the elimination of tumor through increasing the drug dose, combining drugs and repeatedly using drugs, the normal proliferating cells of the body are often destroyed before the tumor is destroyed, which destroys the basic conditions for tumor growth and results in more losses than gains. Moderate chemotherapy is different from the traditional standardized chemotherapy program, which emphasizes on individual chemotherapy program, fully considering the patient’s tolerance level and toxic side effects of chemotherapy. For gastrointestinal adenocarcinoma, oxaliplatin, paclitaxel for squamous cell carcinoma and gemcitabine for pancreatic and biliary carcinoma should be used. Molecular targeted therapy is the most promising treatment for cancer dormancy. Currently, targeted therapeutic drugs mainly include monoclonal antibodies and small molecules, the former of which can inhibit downstream signaling by binding with receptors or antigens on the surface of cells and blood vessels; the latter has a smaller molecular weight and can directly enter cells to block the chemistry of various enzymes in the signaling pathway and play anti-tumor effects. Anti-EGFR monoclonal antibodies such as cetuximab (erbitux, C225) are the first recombinant humanized anti-EGFR monoclonal antibodies that can inhibit tumor growth and prevent neovascularization without affecting normal tissue cells. The drug was approved by the FDA in 2004 for the treatment of colon cancer and was launched in China in July 2006. Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies such as bevacizumab (avastin) is one of the most promising recombinant humanized, human-mouse chimeric anti-VEGF monoclonal antibodies, which can inhibit endothelial cell proliferation and neovascularization and delay tumor growth and metastasis. Small molecule EGFR tyrosine kinase inhibitors such as gefitinib (ERSA) can reduce the synthesis of extracellular matrix in cancer tissues to prevent distant metastasis of tumor cells. In addition, Chinese medicine treatment has good application prospects in the treatment of tumor dormancy because it emphasizes the balance of tumor suppression and regulation of the body. The key points of advanced cancer treatment 1. face up to the existence of tumor and live with tumor for a long time 2. sufficient body resistance and nutritional support to eliminate complications and create conditions for growth with tumor 3. individualized treatment to make tumor dormant without pursuing to make tumor shrink or disappear.